Short peptides derived from the body's own proteins can block the blood vessel formation that tumors need to grow, offering a low-toxicity approach to cancer treatment.
≤50 amino acidsShort peptides derived from thrombospondin, collagens, and other endogenous proteins can block tumor blood vessel formation with low toxicity — several have reached clinical trials
What the researchers found
Multiple anti-angiogenic peptides (50 amino acids or shorter) derived from endogenous proteins like thrombospondin, collagens, chemokines, and growth factors have shown promise in preclinical cancer models and some have reached clinical trials. These peptides work by blocking the formation of new blood vessels that tumors need to grow. Various protein modification strategies — including D-amino acid substitution and non-natural amino acid incorporation — have been used to improve their stability and potency. Computational tools and bioinformatics approaches are accelerating the discovery and optimization of new anti-angiogenic peptide candidates.
Why it matters
Tumors cannot grow beyond a few millimeters without recruiting new blood vessels (angiogenesis). Blocking this process with peptides offers a targeted cancer treatment with low toxicity and high specificity compared to conventional chemotherapy. This review catalogs the diverse landscape of anti-angiogenic peptides, showing that the body already produces proteins containing these vessel-blocking fragments — researchers just needed to identify and optimize them.
The numbers in context
Peptides ≤50 amino acids · Derived from thrombospondin, collagens, chemokines, coagulation proteins, growth factors · Multiple candidates in preclinical/clinical testing · Optimized via L-to-D and non-natural amino acid substitutions
How the study worked
Comprehensive review surveying published preclinical and clinical data on anti-angiogenic peptides of 50 amino acids or fewer. The authors catalogued peptide sources, receptor targets, modification strategies, and technological advances in peptide discovery including computational and bioinformatics tools.
Who was studied
Review of preclinical and clinical studies on anti-angiogenic peptides for cancer therapy
What this study cannot tell us
As a 2011 review, it cannot reflect the more recent clinical outcomes of many of the peptides discussed. Anti-angiogenic therapies as a class have had mixed clinical results — preclinical promise has not always translated to clinical success. The review focuses on peptides ≤50 residues, excluding larger anti-angiogenic proteins that may be more clinically advanced.
How to read the evidence
This is a comprehensive review published in a pharmaceutical biotechnology journal, synthesizing data from numerous preclinical and clinical studies. It provides a thorough landscape overview but is a secondary source rather than original research.
When this study was published
Published in 2011, this review captures the early-to-mid development phase of anti-angiogenic peptide therapeutics. Many of the peptides discussed have since progressed through further development, making some details outdated while the fundamental concepts remain relevant.
The bigger picture
Anti-angiogenic therapy was one of the most exciting concepts in cancer treatment when bevacizumab (Avastin) was approved in 2004. While the reality has been more nuanced than the initial hype, the approach remains an important part of cancer treatment. Peptide-based anti-angiogenic agents offer potential advantages over antibodies — they're smaller, cheaper to produce, and can penetrate tumors more easily. This review captures the state of the field at a pivotal moment and catalogs the diverse molecular toolkit available for blocking tumor blood vessel formation.
Questions still open
- Which of the anti-angiogenic peptides cataloged in this review have progressed furthest in clinical trials since 2011?
- Can anti-angiogenic peptides be combined with immunotherapy or targeted therapy for synergistic anti-cancer effects?
- Why have some anti-angiogenic approaches shown strong preclinical results but disappointing clinical outcomes?
Common questions
How do anti-angiogenic peptides fight cancer?
Why use peptides instead of drugs like Avastin for blocking tumor blood vessels?
Read the original research
Anti-angiogenic peptides for cancer therapeutics.
Current pharmaceutical biotechnology, 12(8), 1101-16
Citation
Rosca, Elena V; Koskimaki, Jacob E; Rivera, Corban G; Pandey, Niranjan B; Tamiz, Amir P; Popel, Aleksander S. (2011). Anti-angiogenic peptides for cancer therapeutics.. Current pharmaceutical biotechnology, 12(8), 1101-16.